• UCLA Health
  • myUCLAhealth
  • School of Medicine
Institute of Urologic Oncology

UCLA Institute of Urologic Oncology

Institute of Urologic Oncology
  • About Us
    • Director's Welcome
    • Board of Directors
    • IUO in the News
    • Why Choose the UCLA IUO
    • Support the IUO
    • Contact Us
    • The Wasserman Building
    • Maps and Directions
    • IUO Membership Information
    • Administrative & Research Staff
    • Positions Available
  • Clinical Programs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Testicular Cancer
    • Integrated Cancer Program
  • Research Programs
    • Clinical Trials
    • Faculty Labs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • SPORE In Prostate Cancer
    • External Funding Opportunities
  • Clinical Trials
    • What Is a Clinical Trial?
    • Who Should Consider Clinical Trials & Why
    • Bladder Cancer Clinical Trials
    • Kidney Cancer Clinical Trials
    • Prostate Cancer Clinical Trials
    • Clinical Research Team
    • IUO Membership Information
  • For Patients
    • Contact Us
    • Clinical Updates
    • Health Plans and Financial Matters
    • Maps and Directions
    • myUCLAhealth
    • Patient Testimonials
    • Preparing for Surgery
    • Webinars / Videos
  • Fellowship
    • Current Fellows
    • Former Fellows
    • Fellow Testimonials
    • UCLA Health Aerial Tour
  • For Healthcare Professionals
    • How to Refer a Patient
    • Lectures & Conferences
    • CTSI Distinguished Speaker Seminar Series
    • DGSOM Research Seminars
    • DGSOM Events
    • JCCC Seminars
    • SPORE Lectures
    • External Funding Opportunities
  • Expert Team
    • Board of Directors
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Institute of Urologic Oncology

Clinical Trials

Clinical Trials

Clinical Trials

  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Information
  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Information
  1. Home
  2. Institute of Urologic Oncology
  3. Clinical Trials
  4. A Study for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

A Study for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Share this

Merck BCG and Pembrolizumab for High-Risk Non-Muscle-Invasive Bladder Cancer

Lay Title:A Study for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Technical Title:A Phase 3 Trial of BCG with or without Pembrolizumab for High Risk Non-Muscle-Invasive Bladder Cancer (KEYNOTE-676)

Disease Type:Patients who have been treated with BCG and have recurrent or persistent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC)

Basic information:The purpose of this research study is to test the safety of pembrolizumab in combination with Bacillus Calmette-Guerin (BCG) and to see how well this combination treatment works compared to BCG alone. Pembrolizumab (MK-3475) has been approved for patients with certain types of bladder cancer; however, it has not been approved for your type of bladder cancer. BCG has been approved for patients with your type of bladder cancer.

Research Procedures (not a complete list): Patients will be randomized to receive BCG alone or BCG in combination with pembrolizumab. The study will be unblinded, so both you and your doctor will know what treatment you will get. 

If you receive pembrolizumab, it will be given by an intravenous (IV) infusion about once every 3 weeks for 2 years. BCG will be given directly into your bladder through a catheter once a week for 6 weeks, then once a week for 3 weeks at Months 3, 6, 12, 18, 24, 30, and 36. During study visits, you will undergo physical exams, cardiac tests, and blood and urine test. You will also undergo cystoscopies (examination to see the inside of your urinary bladder) and CT urograms (CT scan of your urinary tract) periodically.

Eligibility Criteria (not a complete list):
Inclusion Criteria:

  • Diagnosis of non-muscle invasive bladder cancer
  • Prior treatment with only one induction course of BCG, with at least 5 BCG instillations within a 10-week period, with persistent or recurrent NMIBC. Note, patients who received more than one induction course or any maintenance course of BCG is not eligible.
  • Willing to provide tissue for research purposes.

Exclusion Criteria:

  • Muscle invasive, locally advanced non-resectable, or metastatic bladder cancer
  • Urothelial carcinoma outside of the bladder (such as urethra, ureter, renal pelvis)
  • Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, and other similar therapies

For More Detailed Information, Contact:

  • Karim Chamie, MD, Principal Investigator, Associate Professor-in-Residence of UCLA Urology
  • Ankush Sachdeva, Study Coordinator, (310) 794-3421
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest